US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>The company priced a downsized 15.3 million share offering at $18.00, notably above its initial $15–$17 range in late January.</li>
<li>After the biotech sector took a hit in April, Metsera shares rallied back to a high of $47.40 in mid-July, nearly tripling off the lows.</li>
<li>Metsera’s trajectory will be determined by data. With two clinical trials underway and expectations rising, the year-end readout for MET-233i could meaningfully shift the valuation—up or down.</li>
</ul>


The company priced a downsized 15.3 million share offering at $18.00, notably above its initial $15–$17 range in late January.
After the biotech sector took a hit in April, Metsera shares rallied back to a high of $47.40 in mid-July, nearly tripling off the lows.
Metsera’s trajectory will be determined by data. With two clinical trials underway and expectations rising, the year-end readout for MET-233i could meaningfully shift the valuation—up or down.


Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year

<ul>
<li>Metsera (MTSR US), a biotech using peptides to treat obesity, overweight and related conditions opened 41.7% above the issue price. </li>
<li>The company was seeking a specific cash-raise of $275 million and was not looking to allow further dilution.</li>
<li>IPOs in the biotech sector are a "sell-the-news" event until we see on the tape otherwise.</li>
</ul>


Metsera (MTSR US), a biotech using peptides to treat obesity, overweight and related conditions opened 41.7% above the issue price. 
The company was seeking a specific cash-raise of $275 million and was not looking to allow further dilution.
IPOs in the biotech sector are a "sell-the-news" event until we see on the tape otherwise.


Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

<ul>
<li>The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.</li>
<li>According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.</li>
<li>The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".</li>
</ul>


The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.
According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.
The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".


Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

<ul>
<li>Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.</li>
<li>ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.</li>
<li>The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.</li>
</ul>


Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.
ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.
The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.


Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

<ul>
<li>Biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions filed for Q1 IPO</li>
<li>Preliminary Phase 2 results in January suggested a durable pharmacodynamic, or PD, effect consistent with the observed half-life.</li>
<li>ARCH Ventures along with Fidelity are among the existing shareholders as this company enters begins its road to be a publicly traded company</li>
</ul>


Biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions filed for Q1 IPO
Preliminary Phase 2 results in January suggested a durable pharmacodynamic, or PD, effect consistent with the observed half-life.
ARCH Ventures along with Fidelity are among the existing shareholders as this company enters begins its road to be a publicly traded company


Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

United States

Clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Metsera (MTSR US)

Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year

Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i.

IPO Boutique

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

IPO Boutique

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year

​Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i.

IPO Boutique

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

​Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

​Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

IPO Boutique

Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

​Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

IPO Boutique

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

​Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.

IPO Boutique

Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i.

Metsera, a biotech using peptides for obesity, opened 41.7% above issue price in IPO, seeking $275 million without further dilution. Biotech IPOs...

Metsera is set to capitalize on the booming GLP-1 market with a well-timed IPO seeking a mega valuation of $1.8b, putting them in "rare company".

Metsera, Inc. is developing innovative obesity treatments with backing from top investors, aiming for a $2bn IPO valuation.

Biotech company developing NuSH peptides for obesity files for Q1 IPO with promising Phase 2 results and support from ARCH Ventures and Fidelity.